Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingCommunity Health Plan Washington genetic testing C…
    Ask Trek AI about this page
    ModifiedCommunity Health Plan WashingtonPolicy N/A

    Genetic Testing: Aortopathies and Connective Tissue Disorders — Coverage Criteria

    Customize your policy alerts

    Sign up for all Community Health Plan Washington policy alerts

    Know when Community Health Plan Washington releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria for genetic and multigene panel testing to diagnose or confirm hereditary aortopathies and connective tissue disorders for members of the health plan; applies to providers ordering genetic testing for these conditions.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyGenetic Testing: Aortopathies and Connective Tissue Disorders — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeMaterial content and coding revisions
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document disorder-specific clinical features (e.g., aortic root Z‑score, systemic score, family history, or major criteria for vEDS) when ordering genetic testing.
    SourceLink
    POLICY UPDATE CHANGES

    Updated background, references, and added GeneReviews content for FBN1-related Marfan syndrome and other HTAD genes; replaced 'coverage criteria' language with 'criteria'.

    For Other Covered Connective Tissue Disorders, removed CPT codes 81411 and 81410 and adjusted listed codes for testing.

    Updated title to reflect V1.2024 and later V2.2024/V1.2025 versions with multiple content and coding updates.

    Moved Known Familial Variant Analysis criteria to the general genetic testing policy to consolidate known familial variant test criteria.

    Removed minimum gene lists for some multigene panels (e.g., Loeys-Dietz, TAAD) and expanded/modified gene lists for others (e.g., cEDS, FBN1 criteria).

    Clarified that COL3A1 sequencing and targeted resequencing (including CNV detection) are indicated to verify vEDS when clinical features suggest vEDS.

    5Disorder-specific criteria sets
    MultipleCPT code groups referenced
    >20HTAD genes listed
    >2.0Aortic Z-score threshold
    Not appropriatehEDS testing stance
    MultipleDocument revisions

    Coverage Criteria and Disorder-Specific Testing

    Comprehensive Connective Tissue Disorders Multigene Panel

    Covered when the enrollee meets criteria for at least one of the listed disorders.

    Covered indications: Member meets criteria for at least one of: Marfan syndrome, Loeys-Dietz syndrome (LDS), Classic Ehlers-Danlos syndrome (cEDS), or Vascular Ehlers-Danlos syndrome (vEDS)

    Comprehensive panel codes 81410, 81411; panels are investigational for other indications including isolated hypermobility and hEDS

    FBN1 Sequencing and/or Deletion/Duplication Analysis

    Covered when ANY of A or B criteria are met.

    Marfan genetic testing: Member has (A) aortic root enlargement (Z-score ≥2) or aortic dissection, OR ectopia lentis, OR (B) systemic score ≥7 using the listed systemic features (wrist/thumb sign, pectus deformities, hindfoot deformity, pes planus, pneumothorax, dural ectasia, protrusio acetabuli, abnormal segment ratios/arm span, scoliosis/kyphosis, reduced elbow extension, selected facial features, skin striae, myopia, mitral valve prolapse)Z-score ≥2; systemic score ≥7

    Codes 81408, 81479; investigational for other indications

    Loeys-Dietz Syndrome Multigene Panel

    Covered when the enrollee meets at least two listed features.

    LDS genetic testing: Member meets ≥2 of: characteristic facial features (eg, widely spaced eyes, craniosynostosis), bifid uvula or cleft palate, tortuosity of the aorta and its branches, aortic dilatation or dissection, joint hypermobility, OR has a first-degree relative with a clinical diagnosis of Loeys-Dietz syndrome>=2 features

    Codes 81405, 81408, 81479; if both aortic root enlargement and ectopia lentis are present, FBN1 should be included in the panel or previously tested

    Familial Thoracic Aortic Aneurysm and Dissection (TAAD) Multigene Panel

    Covered when ALL of the following are met.

    TAAD genetic testing: A. Member has history of aortic root enlargement OR thoracic aneurysm OR type A/B aortic dissection; AND B. Member does not meet diagnostic criteria for another connective tissue disorder; AND C. Member has family history of dilation or dissection of the aortic root consistent with autosomal dominant inheritance

    Codes 81405, 81406, 81408, 81410, 81411, 81479; multigene HTAD panels per GeneReviews are recommended

    Classic Ehlers-Danlos Syndrome (cEDS) Multigene Panel

    Covered when ALL of the following are met.

    cEDS genetic testing: A. Skin hyperextensibility and atrophic scarring; AND B. Generalized joint hypermobility OR at least three of: easy bruising, soft doughy skin, skin fragility, molluscoid pseudotumors, subcutaneous spheroids, hernia, epicanthal folds, complications of joint hypermobility, OR family history of a first-degree relative with clinical cEDS; AND C. The panel includes at minimum COL5A1 and COL5A2

    Codes 81408, 81479; investigational for other indications including isolated hypermobility and hEDS

    COL3A1 Sequencing and/or Deletion/Duplication Analysis (vEDS)

    Covered when ANY of the listed major criteria or ≥1 listed family/combination criteria are met.

    vEDS genetic testing: Member has any of: arterial rupture/dissection <40 years, spontaneous sigmoid colon perforation without diverticular disease, uterine rupture in third trimester without prior C-section, carotid-cavernous sinus fistula without trauma, OR has a close relative with clinical vEDS; OR member has ≥2 minor criteria (eg, bruising in unusual sites, thin translucent skin, characteristic facial appearance, spontaneous pneumothorax, acrogeria, talipes equinovarus, congenital hip dislocation, small joint hypermobility, tendon/muscle rupture, keratoconus, gingival fragility, early-onset varicose veins)

    Code 81479; investigational for other indications including isolated hypermobility and hEDS; if sequencing is negative, complement with CNV testing

    Diagnostic genetic testing — medically necessary criteria

    Covered when ALL of the following are met for diagnostic genetic testing to establish or confirm specific connective tissue or heritable thoracic aortic disease (HTAD) diagnoses:

    General coverage conditions: Clinical features consistent with the disorder and/or family history suggesting a hereditary connective tissue disorder or HTAD; testing is intended to establish or confirm diagnosis; choice of single-gene vs multigene panel should be guided by phenotype and GeneReviews/ACMG recommendations

    See disorder-specific criteria (Marfan, LDS, TAAD, cEDS, vEDS)

    Disorders and associated genes: Testing to establish or confirm diagnosis for listed connective tissue disorders (examples include arthrochalasia EDS: COL1A1/COL1A2; brittle cornea: ZNF469/PRDM5; cardiac-valvular EDS: COL1A2; cEDS: COL5A1/COL5A2; vEDS: COL3A1 ± COL1A1; HTAD genes: FBN1, ACTA2, MYH11, MYLK, SMAD3, TGFBR1/2, TGFB2/3, LOX, PRKG1, etc.) is medically necessary when clinical features are present

    Specific gene lists per disorder and GeneReviews Table 1 guide panel composition

    Marfan syndrome criteria: A pathogenic FBN1 variant establishes diagnosis in a proband when accompanied by aortic root enlargement (Z-score >2.0) or ectopia lentis; a systemic score ≥7 supports testing

    Molecular testing for vascular Ehlers-Danlos syndrome (vEDS)

    Covered when clinical features suggest vEDS and molecular confirmation is required.

    vEDS testing indications: Testing is indicated when minimal criteria suggestive for vEDS are present (family history of vEDS; arterial rupture or dissection <40 years; unexplained sigmoid colon rupture; spontaneous pneumothorax with other vEDS features), or when a combination of minor features is present; diagnosis requires identification of a causative variant in one allele of COL3A1

    Use Sanger sequencing of COL3A1 or targeted panel including COL3A1 ± COL1A1; if sequencing is negative, perform CNV detection to identify large deletions/duplications

    Genetic testing (either single-gene or multigene panels) for isolated joint hypermobility and for hypermobile Ehlers–Danlos syndrome (hEDS) is considered investigational and not covered when ordered solely for those indications. The policy specifies that comprehensive connective tissue disorder panels (codes 81410, 81411) are medically necessary only when the enrollee meets criteria for at least one of the listed disorders (Marfan syndrome, Loeys–Dietz syndrome, classic EDS, or vascular EDS) and are investigational for other indications including isolated hypermobility and hEDS.

    Genetic testing solely to evaluate for hEDS is not appropriate because, per GeneReviews cited in the policy, hEDS is diagnosed based on clinical evaluation and family history and the causative gene(s) are currently unknown; therefore testing for hEDS alone is considered investigational/not medically necessary.

    The policy states explicitly that genetic testing is not appropriate when requested solely to evaluate for hypermobile Ehlers–Danlos syndrome (hEDS). This statement follows GeneReviews guidance indicating that hEDS is diagnosed clinically (personal and family history) and that the responsible gene(s) have not been identified; accordingly, molecular genetic testing for the sole purpose of assessing hEDS is not appropriate or supported.

    Operational revisions to the policy removed several previously listed minimum gene-list requirements and edited the policy reference table. As part of the semi‑annual reviews (noted in the revision history), the policy replaced some prior minimum gene-list panel language, removed certain comprehensive EDS panel listings, and adjusted CPT/code listings to reference individual codes rather than older grouped code ranges. These edits are documented in the revision entries for V1.2024 and later updates.

    Any genetic testing that does not meet the disorder‑specific criteria described in this policy is considered investigational and may be denied. That includes panels or single‑gene tests ordered for indications outside the listed, syndrome‑specific clinical criteria (for example, testing for isolated hypermobility or testing that lacks the required clinical documentation supporting a covered indication).

    Molecular genetic testing performed solely to evaluate for hEDS is considered not appropriate and therefore not medically necessary. The policy reiterates GeneReviews guidance that hEDS is a clinical diagnosis and that causative gene(s) are currently unknown; requests for genetic testing with the exclusive intent of diagnosing hEDS should not be approved.

    Specific prior minimum gene‑list panel configurations that were previously specified in the policy have been removed and are no longer the primary determinants of coverage. The revision history notes removal of prior minimum gene lists for multiple multigene panels (for example, Loeys–Dietz and TAAD) and replacement of some comprehensive panel language; tests or panel configurations that do not align with the updated policy reference table may not be covered as they were under prior versions.

    Diagnostic genetic testing to establish or confirm a diagnosis of Marfan, Loeys-Dietz, TAAD, cEDS, or vEDS when specified clinical criteria are met

    Diagnostic genetic testing to establish or confirm a diagnosis of Marfan syndrome, Loeys-Dietz syndrome, Familial TAAD, classic Ehlers-Danlos syndrome (cEDS), or vascular Ehlers-Danlos syndrome (vEDS) when specified clinical criteria are met.

    Covered disorders: Testing is medically necessary when the member meets the disorder-specific clinical criteria described for Marfan, LDS, TAAD, cEDS, or vEDS

    See the individual criterion blocks for each disorder (FBN1, LDS genes, TAAD gene sets, COL5A1/COL5A2, COL3A1)

    Establishing or confirming diagnosis of specified connective tissue disorders when clinical features and/or family history are present

    Establishing or confirming diagnosis of specified connective tissue disorders when clinical features and/or family history are present.

    Clinical and family-history basis: Clinical features consistent with the suspected disorder and/or relevant family history (including close relatives with clinical diagnosis or early unexplained sudden death) should be documented to support testing; choice of test guided by phenotype and GeneReviews guidance

    Family history requirements vary by disorder (eg, LDS allows a first-degree relative; TAAD requires autosomal dominant-pattern family history; vEDS allows close relative with clinical vEDS)

    Individuals with clinical features suggestive of vEDS

    Individuals with clinical features suggestive of vEDS: criteria for molecular confirmation via COL3A1 sequencing (± COL1A1) and CNV testing.

    vEDS molecular confirmation: Member has minimal suggestive criteria (family history of vEDS, arterial rupture/dissection <40 years, unexplained sigmoid colon rupture, spontaneous pneumothorax with other vEDS features) or a combination of minor features; molecular confirmation relies on identifying a causative COL3A1 variant

    Verify by Sanger sequencing of COL3A1 or targeted panel including COL3A1 ± COL1A1; if no variant is found, perform CNV detection for large deletions/duplications

    Provider Actions, Documentation, and Prior Authorization

    Prior Authorization

    Prior authorization required for listed CPT codes

    Prior authorization is required for the listed multigene panel and single-gene CPT codes and coverage is limited to clinically indicated situations per the disorder-specific criteria.

    • Applies to CPT codes including 81400–81408, 81410, 81411, and 81479 as listed in the coding table.
    • If a panel is performed, the appropriate panel CPT code (e.g., 81410, 81411) should be used.
    Prior Authorization

    Prior authorization for genetic panels is subject to coverage review

    Genetic testing for the listed connective tissue disorders and heritable thoracic aortic disease (HTAD)—whether single-gene or multigene panels—is subject to coverage criteria and may require prior authorization per the payer's General Approach to Genetic and Molecular Testing.

    • Panel testing should be guided by phenotype and GeneReviews/ACMG guidance.
    • Multigene panels are recommended where phenotype/family history suggest HTAD (see GeneReviews Table 1).

    Coding and Billing References

    Covered CPT Codes (panels and single-gene)CPTCovered
    81410Comprehensive connective tissue disorders multigene panel
    81411Comprehensive connective tissue disorders multigene panel (add-on)
    81408FBN1 sequencing and/or deletion/duplication analysis
    81479Unlisted molecular pathology procedure (used for some single-gene tests in document)
    81405Targeted multigene panel (used for LDS, TAAD panels)
    81406Targeted multigene panel (TAAD)
    81400Molecular genetics procedure (other covered connective tissue disorders)
    81401Molecular genetics procedure
    81402Molecular genetics procedure
    81403Molecular genetics procedure
    1–10 of 12
    1/2
    Example ICD-10 Codes referencedICD-10
    I71.00-I71.9Aortic aneurysm and dissection ICD-10 range (used as example ICD codes)
    M35.7Systemic involvement notation (example ICD)
    Q79.60Congenital musculoskeletal anomalies (example ICD)
    Q79.61Congenital musculoskeletal anomalies (example ICD)
    Q79.63Congenital musculoskeletal anomalies (example ICD)
    Q79.69Congenital musculoskeletal anomalies (example ICD)
    Q12.1Congenital malformation of unspecified bone (example ICD)
    Q87.4Other congenital malformation syndromes predominantly affecting limbs (example ICD)
    Q87.5Other congenital malformation syndromes predominantly affecting connective tissue (example ICD)
    M35.7Systemic involvement (repeated example ICD)
    Covered genetic testing CPT codes mentionedCPTCovered
    81400Genomic sequencing procedure, 1-10 kb
    81401Genomic sequencing procedure, 10-100 kb
    81402Genomic sequencing procedure, 100-500 kb
    81403Genomic sequencing procedure, 500 kb-1 Mb
    81404Genetic test panel, multiple genes (unspecified)
    81405Targeted sequence analysis
    81406Targeted sequence analysis, multiple regions
    81407Deletion/duplication analysis
    81408Duplication/deletion testing, larger panels
    Referenced CPT Codes / Coding table notesCPT
    81411Tiered or multiple gene sequencing (example code listed/modified in policy reference table)
    81410Another multigene sequencing code referenced as removed in some lists and adjusted to individual codes
    Marfan systemic score threshold
    Marfan systemic score threshold>= 7
    Source for calculationPoint-based systemic score per Marfan.org listed in policy (features and point values)
    Use in coverage criteriaSystemic score >=7 supports eligibility for FBN1 testing to confirm Marfan syndrome
    Aortic root enlargement Z-score
    Aortic root enlargement Z-score threshold (policy)>= 2
    Interpretation noteZ-score must be standardized for age and body size; Z-score >2.0 indicates ≥95th percentile

    Tests and Indications Not Covered

    Testing solely to evaluate for hypermobile Ehlers–Danlos syndrome (hEDS) and testing for isolated hypermobility are specifically listed as not covered. The policy marks panels and single‑gene testing for these indications as investigational given the lack of known causative genes for hEDS and GeneReviews guidance that hEDS diagnosis is clinical rather than genetic.

    The policy explicitly states that genetic testing solely for hypermobile Ehlers–Danlos syndrome (hEDS) is not covered because the causative gene(s) for hEDS are currently unknown and hEDS is diagnosed on clinical grounds and family history per GeneReviews.

    Certain previously specified minimum‑gene‑list panels and older CPT groupings were removed from the policy reference table during revisions. The revision history documents removal of prior minimum gene lists for several multigene panels and changes to how panel CPTs are listed (individual codes rather than ranges); these removed configurations are no longer supported as primary coverage criteria under the updated policy.

    Definitions and Key Terms

    hEDS (hypermobile Ehlers-Danlos syndrome)
    DefinitionhEDS (hypermobile Ehlers-Danlos syndrome) is diagnosed based on clinical evaluation and family history; causative genes are currently unknown
    Role of genetic testingGenetic testing is not appropriate solely to evaluate for hEDS; testing for other EDS subtypes is addressed separately
    Policy implicationRequests for genetic testing solely for isolated hypermobility or hEDS are considered investigational/not medically necessary
    Marfan systemic score
    DefinitionMarfan systemic score: a point-based system (per Marfan.org) tallying specific clinical features
    Diagnostic threshold>= 7 total points supports systemic involvement for Marfan syndrome

    Background and Clinical Context

    Hereditary connective tissue disorders commonly affect multiple organ systems and frequently present with joint hypermobility and cardiovascular manifestations such as thoracic aortic aneurysm and dissection. Clinical diagnosis can be challenging; when a genetic cause is known and supported by the policy's syndrome‑specific criteria, genetic testing can establish a diagnosis that affects management (for example, aortic surveillance and surgical decision‑making). The policy emphasizes that hEDS is a clinical diagnosis and that molecular testing is not appropriate for hEDS alone.

    Covered Indications Summary

    Diagnostic genetic testing to establish or confirm a diagnosis of Marfan, Loeys-Dietz, TAAD, cEDS, or vEDS when specified clinical criteria are met (summary)

    Summary: Diagnostic genetic testing to establish or confirm Marfan, Loeys-Dietz, TAAD, cEDS, or vEDS when disorder-specific clinical criteria are met.

    Summary coverage: Genetic testing (single-gene or multigene panel) is covered when the member meets the specific clinical criteria for one of the listed connective tissue disorders; test selection should align with phenotype and GeneReviews/ACMG guidance

    Panels and single-gene tests use CPT codes listed in the policy; testing solely for hEDS or isolated hypermobility is investigational

    Establishing or confirming diagnosis of specified connective tissue disorders when clinical features and/or family history are present

    Establishing or confirming diagnosis of specified connective tissue disorders when clinical features and/or family history are present.

    Clinical rationale: Use GeneReviews and professional guidance to select gene-specific testing; document clinical features (aortic Z-score, ectopia lentis, systemic score, major/minor criteria) and relevant family history to support testing

    Revision History and Policy Changes

    2023-03operational_update

    Policy developed and semi-annual review; title updated to V1.2024; background, coding reference table, and references updated; replaced phrase 'coverage criteria' with 'criteria'; removed 'Comprehensive Ehlers-Danlos Syndrome Multigene Panels' from policy reference table and removed CPT codes 81411 and 81410 from Other Covered Connective Tissue Disorders listing.

    2023-10criteria_update

    Moved Known Familial Variant Analysis criteria to the general genetic testing policy to consolidate familial variant test criteria; expanded FBN1 criteria to better align with guidelines and cover individuals with clinical Marfan diagnosis.

    2024-04
    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyGenetic Testing: Aortopathies and Connective Tissue Disorders — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeMaterial content and coding revisions
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document disorder-specific clinical features (e.g., aortic root Z‑score, systemic score, family history, or major criteria for vEDS) when ordering genetic testing.
    SourceLink
    On This Page
    Coverage Criteria and Disorder-Specific TestingProvider Actions, Documentation, and Prior AuthorizationCoding and Billing ReferencesTests and Indications Not CoveredDefinitions and Key TermsBackground and Clinical ContextCovered Indications SummaryEligibility RequirementsRevision History and Policy Changes
    Z-score >2.0; systemic score ≥7

    GeneReviews guidance; aortic size should be standardized to age/body size

    HTAD testing recommendation: Multigene panels that include known HTAD genes are recommended when phenotype or family history suggest heritable thoracic aortic disease

    Per Heritable Thoracic Aortic Disease GeneReviews and professional guidance

    Prior Authorization

    Coding updates affect prior authorization

    Certain multigene panel and single-gene tests in the coding/reference table were modified (individual CPTs listed rather than ranges); prior authorization requirements follow the policy's updated coding/reference table.

    • Policy edits removed some prior grouped codes and replaced them with specific CPT listings—prior authorization must reference the current coding table.
    • Providers should confirm the exact CPT code(s) submitted match the policy's coding list to ensure appropriate prior auth processing.
    Note

    Operational and policy-change reminder (provider impact)

    Providers should note policy updates may change coverage and authorization procedures; consult the current policy and payer resources for operational changes.

    Note

    Panel‑first approach recommended (informational)

    Multigene panels are recommended as a first‑line approach in many clinical scenarios where phenotype and family history suggest a hereditary connective tissue disorder or HTAD, consistent with GeneReviews and guideline recommendations (informational only).

    • GeneReviews and ACMG guidance support use of multigene panels rather than serial single‑gene testing when clinical findings suggest disorders such as LDS or HTAD.
    • This is informational and does not replace disorder‑specific medical necessity criteria in the policy.
    Note

    Confirm current panel content and coding before ordering

    Providers should verify coding and criteria details against the current policy when ordering, as prior panel configurations and minimum gene lists were revised; confirm test content meets policy expectations.

    Documentation Required

    Document aortic root Z‑score, ectopia lentis, or systemic score for Marfan (FBN1) testing

    For FBN1 testing to confirm Marfan syndrome, documentation must support aortic root enlargement (Z‑score ≥2) or dissection, ectopia lentis, or a systemic score ≥7 using the policy's listed systemic features.

    • Aortic root enlargement is defined as a Z‑score ≥2, standardized to age and body size.
    • If systemic score pathway is used, document the component features and point totals per the policy (≥7 required).
    Documentation Required

    Document ≥2 LDS clinical features or qualifying family history

    Documentation for Loeys‑Dietz testing must show the member meets at least two listed clinical features OR has a first‑degree relative with a clinical diagnosis of LDS.

    • List qualifying features (e.g., characteristic facial features, bifid uvula/cleft palate, arterial tortuosity, aortic dilatation/dissection, joint hypermobility).
    • If family history is used, document relation (first‑degree) and the relative's clinical diagnosis.
    Documentation Required

    Document clinical aortic disease and AD family history for TAAD panels

    For TAAD multigene panel coverage, document a history of aortic root enlargement, thoracic aneurysm, or type A/B aortic dissection, absence of diagnostic criteria for another connective tissue disorder, and a family history of dilation/dissection consistent with autosomal dominant inheritance.

    • Include imaging or surgical reports documenting aortic enlargement/aneurysm/dissection.
    • Document family history details consistent with autosomal dominant inheritance.
    Documentation Required

    Document cEDS clinical features and panel gene content (COL5A1/COL5A2)

    For classic EDS (cEDS) panel coverage, document skin hyperextensibility with atrophic scarring plus either generalized joint hypermobility or at least three listed supportive features, and confirm the panel includes at minimum COL5A1 and COL5A2.

    • Supportive features include easy bruising, soft doughy skin, skin fragility, molluscoid pseudotumors, subcutaneous spheroids, hernia, epicanthal folds, complications of joint hypermobility, or first‑degree relative with clinical cEDS.
    • Confirm test includes COL5A1 and COL5A2 in report or test order.
    Documentation Required

    Document major/minor criteria or family history for vEDS (COL3A1) testing

    For COL3A1 testing to evaluate vEDS, documentation must show one major criterion (e.g., arterial rupture/dissection <40 years, spontaneous sigmoid colon perforation, third‑trimester uterine rupture without prior C‑section, CCSF without trauma) or two or more minor criteria, or a close relative with clinical vEDS.

    • Major features include arterial rupture/dissection <40 years, spontaneous sigmoid colon perforation, uterine rupture in third trimester without prior C‑section, or carotid‑cavernous sinus fistula without trauma.
    • Minor features encompass bruising, thin translucent skin, characteristic facial appearance, spontaneous pneumothorax, tendon/muscle rupture, keratoconus, gingival fragility, early varicose veins, etc.
    Documentation Required

    Provide clinical features and family history to support testing requests

    Providers should include clinical details that support the requested genetic test: aortic root Z‑score, presence/absence of ectopia lentis, systemic score components, family history specifics, and major/minor criteria for EDS subtypes as relevant.

    • Attach imaging, ophthalmology, surgical, or genetic family history documentation to the prior authorization or test order.
    • Document rationale for single‑gene versus multigene panel selection based on phenotype and GeneReviews/ACMG guidance.
    Documentation Required

    Include vEDS‑specific presenting features and plan for CNV testing when indicated

    For vEDS testing specifically, include documentation of presenting features suggestive of vEDS (family history, arterial rupture/dissection <40 years, unexplained sigmoid colon rupture, spontaneous pneumothorax with other vEDS features) and the rationale for molecular testing of COL3A1 (and COL1A1 when relevant).

    • If sequencing is negative, document plan or performance of CNV detection (deletion/duplication) to identify large deletions/duplications.
    • Note that diagnosis rests on identification of a causative variant in one allele of COL3A1.
    Denial Risk

    Indications outside specified criteria may be denied as investigational

    Multigene panels and single‑gene tests performed for indications outside the policy's disorder‑specific medical necessity criteria (for example isolated hypermobility or evaluation solely for hEDS) are considered investigational and may be denied.

    • hEDS is diagnosed clinically and genetic testing solely for hEDS is not appropriate per GeneReviews.
    • Panel requests for indications not supported by the policy should be expected to be denied as investigational.
    Denial Risk

    Testing outside disorder‑specific criteria may be denied

    Testing performed outside the specified medical necessity criteria for each disorder (single‑gene or panel) may be denied as investigational; ensure requests meet the gene‑ or syndrome‑specific coverage nodes before ordering.

    • Confirm the enrollee meets at least one qualifying node for the disorder being tested (e.g., Marfan, LDS, TAAD, cEDS, vEDS).
    • Requests lacking documented criteria are at risk of denial.
    Denial Risk

    Genetic testing solely for hEDS is not appropriate

    Requests for genetic testing solely to evaluate for hypermobile Ehlers‑Danlos syndrome (hEDS) are not appropriate and may be denied because hEDS is diagnosed clinically and causative genes are currently unknown.

    • Do not order genetic testing solely to evaluate hEDS; document alternative reasons if testing is requested (e.g., suspicion for another EDS subtype).
    Denial Risk

    Missing vEDS clinical indication or complementary testing risks denial

    Failure to document clinical features suggestive of vEDS (e.g., family history, arterial rupture/dissection <40 years, unexplained sigmoid colon rupture, spontaneous pneumothorax with other vEDS features) or failure to order appropriate COL3A1 sequencing and complementary CNV testing when indicated may lead to denial.

    • Document major/minor criteria or family history when requesting COL3A1 testing.
    • If sequencing is negative, document CNV testing or plan to perform deletion/duplication analysis.
    Step Therapy

    Order testing in appropriate clinical context per GeneReviews/ACMG

    Order genetic testing in the context of appropriate clinical evaluation and counseling per GeneReviews and ACMG recommendations; testing should be performed when clinical features and family history meet the policy criteria.

    • GeneReviews and ACMG guidance support phenotype‑driven test selection and inform panel composition.
    • Include pre‑test counseling as implied by guidance given testing implications for treatment and family recurrence risk.
    Documentation Required

    Provide or document genetic counseling when ordering/testing

    Given implications for treatment, natural history, and recurrence risk, provide or document genetic counseling (pre‑ and/or post‑test) when ordering testing, as implied by GeneReviews and ACMG references.

    • Counseling is implied though not explicitly mandated in the policy; document that counseling was provided or offered in the medical record or prior auth submission.
    • Consider referral to genetics specialists when available.
    Step Therapy

    Order testing following evaluation by experienced providers

    Order testing only after appropriate clinical evaluation by providers experienced in diagnosing connective tissue disorders; the policy expects professional judgment in selection of single‑gene versus panel testing.

    • Document the evaluating provider's specialty or clinical rationale when relevant.
    • Policy does not prescribe which specialties may order testing; providers are expected to use clinical judgment.
    Note

    Policy does not replace clinical judgment — providers must use professional judgment

    Providers are expected to exercise professional medical judgment; the policy is guidance and does not replace clinician judgment when deciding to order genetic testing.

    Use in coverage criteriaAortic root Z-score ≥2 qualifies as a major criterion for FBN1 testing to confirm Marfan syndrome
    Aortic root enlargement (Z-score)
    Aortic root enlargement (Z-score) clinical threshold> 2.0 (suspicious for Marfan syndrome; >3.0 is >=99th percentile)
    Percentile interpretation>2.0 ≈ ≥95th percentile; >3.0 ≈ ≥99th percentile
    Measurement guidanceAortic size must be standardized to age and body size for accurate interpretation
    Age threshold for considering vEDS features
    Age threshold for arterial events suggestive of vEDS< 40 years (arterial rupture or dissection in individuals less than 40 years of age)
    Other vEDS major features prompting testingUnexplained sigmoid colon rupture or spontaneous pneumothorax with other vEDS features
    ActionPresence of arterial rupture/dissection <40 should lead to diagnostic molecular testing of COL3A1
    Use in testing criteriaA systemic score >=7 is one criterion that can qualify a member for FBN1 sequencing/deletion-duplication analysis
    Close relatives
    First-degree relativesParents, siblings, and children
    Second-degree relativesGrandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings
    Third-degree relativesGreat grandparents, great aunts, great uncles, great grandchildren, and first cousins
    Aortic dissection types (Type A vs Type B)
    Type A aortic dissectionOccurs at the ascending part of the aorta, just as it branches off of the heart
    Type B aortic dissectionOccurs at the descending part of the aorta and may extend into the abdomen
    Clinical relevanceClassification guides management and is referenced in TAAD diagnostic criteria
    vEDS
    DefinitionvEDS (vascular Ehlers-Danlos syndrome) is a connective tissue disorder typically caused by pathogenic heterozygous variants in COL3A1
    Primary gene associationsMost patients have COL3A1 variants; rare exceptions include specific heterozygous variants in COL1A1
    Testing implicationMolecular confirmation via COL3A1 sequencing (± COL1A1) and CNV analysis is indicated when clinical features suggest vEDS

    Providers should document clinical features and rationale for ordered test; family history definitions include first- through third-degree relatives

    vEDS-specific covered indications — individuals with clinical features suggestive of vEDS requiring molecular confirmation

    vEDS-specific covered indications — individuals with clinical features suggestive of vEDS requiring molecular confirmation.

    vEDS-specific indications: Testing indicated for individuals with minimal suggestive criteria (family history of vEDS; arterial rupture/dissection <40 years; unexplained sigmoid colon rupture; spontaneous pneumothorax with other vEDS features) or combination of minor features; molecular confirmation requires identifying a causative COL3A1 variant

    Use Sanger sequencing of COL3A1 or targeted panel including COL3A1 ± COL1A1; if sequencing is negative, perform CNV detection to identify deletions/duplications

    coding_and_criteria_revision

    Removed minimum gene lists for Loeys-Dietz and TAAD panels; expanded cEDS gene list and removed COL1A1 from minimum list; updated coding reference table to list individual CPT codes rather than ranges and made minor wording clarifications across criteria.

    2024-11content_and_reference_updateLatest

    Semi-annual review and updated title to V1.2025; removed older ACMG reference for FBN1 as outdated; updated Background and Rationale with GeneReviews language regarding COL5A1/COL5A2 sequencing and removed prior recommended diagnostic wording for TAAD.

    Change log highlights: semi‑annual reviews resulted in title updates (V1.2024, V2.2024, V1.2025), background and references updates, and replacement of some prior 'coverage criteria' wording with 'criteria'. The policy removed certain previously recommended minimum gene lists for panels (e.g., Loeys–Dietz and TAAD) and adjusted panel and CPT references (removing grouped CPT listings and listing individual CPTs). In addition, Known Familial Variant Analysis criteria were relocated to the general genetic testing policy for consolidation. These revisions are recorded in the policy's revision history entries.